|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 167.50 GBX | 0.00% |
|
+0.30% | +30.86% |
| Feb. 06 | Hargreave Hale AIM asset value falls after "eventful" first quarter | AN |
| Jan. 15 | TruFin lifts outlook, Abingdon reports revenue gain | AN |
| Capitalization | 142M 194M 163M 149M 263M 17.61B 275M 1.73B 689M 8.48B 729M 714M 29.98B | P/E ratio 2025 * |
-
| P/E ratio 2026 * | - |
|---|---|---|---|---|---|
| Enterprise value | 133M 182M 153M 139M 246M 16.44B 257M 1.61B 643M 7.92B 681M 667M 27.99B | EV / Sales 2025 * |
3.45x | EV / Sales 2026 * | 2.68x |
| Free-Float |
65.66% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Diaceutics PLC
| 1 week | +0.30% | ||
| Current month | -1.47% | ||
| 1 month | +18.79% | ||
| 3 months | +2.13% | ||
| 6 months | +21.82% | ||
| Current year | +30.86% |
| 1 week | 166 |  | 170 |
| 1 month | 140 | | 176.25 |
| Current year | 125 | | 176.25 |
| 1 year | 106 | | 176.25 |
| 3 years | 79 | | 176.25 |
| 5 years | 74 | | 176.25 |
| 10 years | 74 | | 195 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ryan Keeling
CEO | Chief Executive Officer | 42 | 2023-12-31 |
Nick Roberts
DFI | Director of Finance/CFO | - | 2022-03-17 |
Gillian Shaw
CMP | Compliance Officer | - | 2022-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Keeling
CHM | Chairman | 65 | 2024-09-30 |
Ryan Keeling
BRD | Director/Board Member | 42 | - |
Jordan Clark
BRD | Director/Board Member | 42 | 2024-09-30 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +0.30% | +22.26% | +65.02% | 194M | |
| -1.90% | +13.56% | +125.88% | +367.80% | 23.11B | |
| 0.00% | -3.79% | +75.77% | +28.49% | 4.44B | |
| +0.24% | +6.68% | +104.05% | +195.13% | 4.36B | |
| -0.03% | +0.03% | -28.15% | +18.36% | 2.98B | |
| +3.71% | +4.60% | -1.31% | +263.29% | 2.7B | |
| +7.57% | +10.59% | -2.04% | +0.92% | 1.9B | |
| +4.37% | +12.63% | +15.41% | -19.48% | 1.57B | |
| -0.66% | +1.57% | +5.61% | +0.22% | 1.43B | |
| Average | +1.51% | +6.77% | +35.27% | +102.20% | 4.74B | |
| Weighted average by Cap. | -0.18% | +5.06% | +85.37% | +239.61% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 38.5M 52.63M 44.22M 40.32M 71.25M 4.77B 74.43M 468M 186M 2.3B 197M 193M 8.12B | 47.9M 65.47M 55.02M 50.16M 88.63M 5.93B 92.59M 582M 232M 2.86B 246M 240M 10.1B |
| Net income | -400K -547K -459K -419K -740K -49.52M -773K -4.86M -1.94M -23.86M -2.05M -2.01M -84.31M | -1.8M -2.46M -2.07M -1.88M -3.33M -223M -3.48M -21.88M -8.72M -107M -9.23M -9.04M -379M |
| Net Debt | -9.44M -12.9M -10.84M -9.88M -17.47M -1.17B -18.25M -115M -45.72M -563M -48.4M -47.39M -1.99B | -13.72M -18.75M -15.76M -14.37M -25.38M -1.7B -26.52M -167M -66.44M -818M -70.34M -68.88M -2.89B |
Employees
213
Sector
Business Support Services
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-02-11 | 167.50 p | 0.00% | 2,485 |
| 26-02-10 | 167.50 p | 0.00% | 67,486 |
| 26-02-09 | 167.50 p | +0.90% | 19,907 |
| 26-02-06 | 166.00 p | -1.19% | 381,243 |
| 26-02-05 | 168.00 p | +0.60% | 59,056 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.675GBP
Average target price
2.206GBP
Spread / Average Target
+31.70%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DXRX Stock
Select your edition
All financial news and data tailored to specific country editions
